SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CNTB

Connect Biopharma Holdings Ltd (NASDAQ:CNTB)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.59-$0.04 (-6.08%)
 
Market cap
$38.0M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 19, 2021
Market Cap$38.05M-79.7%
Revenue (ttm)$2.77M-88.7%
Net Income-$33.43M-9.2%
EPS-$0.53+24.3%
Shares Out64.49M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume365,982
Open$0.64
Previous Close$0.63
Day's Range$0.59 - $0.64
52-Week Range$0.55 - $3.82
Betan/a
AnalystsBuy
Price Target$7.25(+1128.81%)
Earnings DateMar 30, 2027

About CNTB

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Address
3580 Carmel Mountain Road, San Diego, CA, 92130, US
Market Cap
38 million
Employees
64
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$4.37M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $6.75 (+1044.1%)

4 firms rating CNTB in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From CNTB’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-6.08%
5 Days
-12.54%
1 Month
-22.58%
6 Months
-74.89%
1 Year
-79.73%

$CNTB stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CNTB holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CNTB's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CNTB Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New CNTB patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CNTB from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CNTB

IWMiShares Russell 2000 ETF$233.04K
IWOiShares Russell 2000 Growth ETF$72.59K
VTWOVanguard Russell 2000 ETF$69.86K
IWNiShares Russell 2000 Value ETF$67.29K
IWCiShares Micro-Cap ETF$26.64K
VTWGVanguard Russell 2000 Growth ETF$7.92K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CNTB’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
15.57
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$4.37M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

FSEGFidelity Enhanced Small Cap Growth ETF0.00%

Weight is the stock’s share of each fund’s holdings.